Innovative RNA therapeutics

Thalia is a clinical-stage biotechnology company developing innovative RNA therapeutics for high-value unmet needs in oncology and cardiovasular disease.

We are focused on unlocking the full therapeutic potential of RNA by overcoming the fundamental challenges of delivery and enabling targeted, scalable and clinically meaningful medicines for patients.

approach pipeline technology

Advancing RNA medicines through delivery innovation

RNA therapeutics have the potential to transform the treatment of disease, but effective delivery remains the key challenge. Thalia Therapeutics is developing proprietary RNA delivery technologies (Nuvec®) designed to address these challenges, enabling multi-RNA loading, flexible targeting and the potential for oral delivery.

Nuvec® is based on amorphous silica and has an irregular surface structure that simply and effectively traps and protects RNA as it travels to target cells. Nuvec® silica nanoparticles can be readily functionalised to target specific tumour types or organs and have a large surface area, allowing high loading and delivery of RNA drug cargos to their site of action.

By combining delivery innovation with a disciplined, capital-efficient development strategy, we are building a diversified pipeline with multiple value drivers across high-growth therapeutic areas.

A differentiated and expanding pipeline

Thalia Therapeutics has a growing pipeline of RNA programs across oncology and cardiovascular disease, including:

A first-in-class microRNA therapeutic for the treatment of Acute Myeloid Leukemia (AML) with the potential to reduce treatment resistance, high relapse rates and improve survival
A bispecific cardiovascular siRNA program addressing a major unmet need in Atherosclerotic Cardiovascular Disease (ASCVD)
A proprietary RNA delivery technology with broad applicability across multiple RNA modalities and indications

Our strategy is to advance internal programs to generate high-quality clinical and preclinical data while creating opportunities for partnering and licensing.

Proprietary RNA delivery capabilities

Thalia has developed proprietary Nuvec® RNA delivery technologies designed to overcome key barriers to RNA therapeutic development. These technologies enable:

Multi-RNA loading
Flexible targeting
Broad applicability across RNA modalities

Nuvec® is based on amorphous silica and has an irregular surface structure that simply and effectively traps and protects RNA as it travels to target cells. Nuvec® silica nanoparticles can be readily functionalized to target specific tumour cell types or organs and have a large surface area, allowing high loading and delivery of RNA drug cargos to the targeted site of action.

Nuvec® delivery technologies are scalable, well tolerated and designed for repeatable application across multiple therapeutic areas, creating opportunities both within Thalia’s own pipeline and through external strategic partnerships.

‍

Innovative RNA therapeutics

Advancing RNA medicines through delivery innovation

A differentiated and expanding pipeline

Proprietary RNA delivery capabilities

News from Thalia

Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.